LONDON (Alliance News) - Scancell Holdings PLC said Tuesday that data from its second vaccine from its Moditope platform, Modi-2, showed T-cell response, tumour rejection and increased survival in murine models.
The company, which focuses on developing immunotherapies for the treatment of cancer, said that preclinical data for Modi-2 demonstrated that homocitrullinated peptides induce highly potent T cell responses.
"We are pleased to be able to provide an update on the progress of our second Moditope vaccine, Modi-2. The data clearly demonstrates the potential of homocitrullinated, as well as citrullinated, tumour-associated peptide epitopes to be developed for the treatment of solid cancers," Chief Scientific Officer Lindy Durrant said.
Scancell's first vaccine, Modi-1, acts by stimulating the production of CD4 T cells using citrullinated tumour-associated peptide epitopes, which overcome self-tolerance and destroy tumour cells.
While, Modi-2 exploits a new modification, stimulating the production of CD4 T cells using homocitrullinated tumour-associated peptide epitopes.
Scancell shares closed up 0.2% at 7.77 each Tuesday.
Scancell Holdings (SCLP)